Soligenix, Inc. (SNGX)

Quick facts

Phase 3 pipeline

• SGX301 (synthetic hypericin) · Oncology; Dermatology
  SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications.
• SGX942 · Wound healing
  SGX942 is a recombinant human platelet-derived growth factor isoform BB (PDGF-BB) used to promote wound healing.

Phase 2 pipeline

• Mechlorethamine Topical Gel

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Soligenix, Inc. portfolio CI brief
• Soligenix, Inc. pipeline updates RSS